TC
ABCL icon

Telemus Capital’s AbCellera Biologics ABCL Stock Holding History

Telemus Capital’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-13,400
Closed -$295K – 354
2021
Q2 		$295K Sell
13,400
-10,300
-43% -$284K 0.02% 289
2021
Q1 		$666K Buy
23,700
+15,700
+196% +$625K 0.05% 246
2020
Q4 		$322K Buy
+8,000
New +$366K 0.02% 306

Other funds holding ABCL

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
SM
SB Management Abu Dhabi, United Arab Emirates $516M AUM 40.71% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
GCAC
Guardian Capital Advisors (Canada) Toronto, Ontario, Canada $1.02B AUM 25.29% 1-Year Est. Return
FFVM
Founders Fund VII Management San Francisco, California $2.03M AUM 72.34% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Telemus Capital's ABCL Position: Q3 2021 in Review

Telemus Capital sold out of AbCellera Biologics (ABCL) in Q3 2021, closing a stake of 13,400 shares — an estimated $295K sold.

Telemus Capital first reported a position in ABCL in Q4 2020 and held it in 3 quarters. The position peaked at $666K in Q1 2021. 116 funds tracked by Wall St. Rank hold ABCL as of Q3 2021.

  • Telemus Capital reported no remaining AbCellera Biologics position as of Q3 2021 after selling out during the quarter.
  • Telemus Capital sold 13,400 AbCellera Biologics shares in Q3 2021, an estimated $295K.
  • Telemus Capital first reported a position in AbCellera Biologics in Q4 2020 and held it in 3 quarters.
  • Telemus Capital's AbCellera Biologics position peaked at $666K in Q1 2021.
  • 116 funds tracked by Wall St. Rank held AbCellera Biologics as of Q3 2021.

Based on Telemus Capital's 13F filing for Q3 2021, filed 27 Oct 2021.